In particular, the risk of in-hospital mortality, acute heart failure, and acute kidney injury requiring RRT in patients taking GLP-1 RA/SGLT-2i therapy was intermediate between that of patients without DM and that of DM patients not taking these drugs (Fig. 4). This evidence concerns the gene GLP1R and acute kidney injury.